[Results of a multicenter study of Rebif-22 mcg administration in Russia].
The results of multicenter study of Rebif 22 micrograms in Russia have been reported. 167 multiple sclerosis patients have received Rebif 22 micrograms three times a week for 1 year. This study provides evidence for reduction of the relapse rate in patients with relapsing/remitting and secondary progressive multiple sclerosis. The tendency to the decrease of the severity of relapses, less need for steroid use and the decrease of EDSS score in patients with relapsing/remitting multiple sclerosis have been shown. In general Rebif 22 micrograms was tolerated well.
Zavalishin
I A
IA
Gusev
E I
EI
Iakhno
N N
NN
Skoromets
A A
AA
Boĭko
A N
AN
Demina
T L
TL
Burlutskiĭ A P
Beĭn
B N
BN
Sholomov
I I
II
Pereserdova
A V
AV
Stoĭda
N I
NI
Zakharova
M N
MN
Adarcheva
L S
LS
Niiazbekova
A S
AS
Askarova
L Sh
LSh
Oleĭnikov
V G
VG
Rebrova
O Iu
OIu
Shmidt
T E
TE
Davydovskaia
M V
MV
Totolian
N A
NA
Beskhmel'nitsina
I A
IA
Bragina
O V
OV
Ponomareva
G L
GL
Durseneva
O M
OM
Voronchikhina
S A
SA
Volkova
L I
LI
Turova
E L
EL
Streknev
A G
AG
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012720:Severity of Illness Index
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a